COVID-19 UPDATE: We understand those living with multiple sclerosis (MS) and their loved ones may be facing a high level of uncertainty during this serious health situation. Patient safety is Genentech’s highest priority. As a company, we are taking COVID-19 seriously and are committed to keeping the communities we serve updated with any new information we learn that could help inform health decisions related to our medicines. We believe that treatment decisions are personal and should be made between patients and their healthcare teams so please reach out to your neurologist or medical professional with questions. In addition to local Public Health guidance, or local guidance specifically issued by medical or patient associations, more information about COVID-19 can be found on the Centers for Disease Control’s (CDC) website or the World Health Organization’s website.

Ocrelizumab website
  • Updated safety analysis
  • Safety topics
  • Post-marketing commitments
MedInfo FAQs Glossary Roche logo
  • Progressive multifocal leukoencephalopathy
  • Malignancies
  • Infections
  • COVID-19
  • Pregnancy and lactation
  • Serum Ig levels
  • Progressive multifocal leukoencephalopathy
  • Malignancies
  • Infections
  • COVID-19
  • Pregnancy and lactation
  • Serum Ig levels
Medical info request

Sitemap

Homepage
Updated safety analysis
Safety topics
Progressive multifocal leukoencephalopathy
Malignancies
Infections
COVID-19
Pregnancy and lactation
Serum Ig levels
Post-marketing commitments
FAQs
Glossary
Login
Confirmation

Legal Statement
|
Privacy Policy
|
Sitemap
|
Cookies Settings
© F. Hoffmann La-Roche Ltd. |
This site is intended for healthcare professionals only, outside the US.
M-XX-00010195 Date of preparation: June 2022

To request a copy of your local ocrelizumab prescribing information, please click here

Third party popup

You are now leaving the site. Are you sure?

Continue